HR Execs on the Move

Y Prime

www.y-prime.com

 
The process that we follow for all projects is simple: we translate real-world experiences into expert advice. Whether this is through consulting or software applications, we align our entire organization to help you solve the specifics of challenges faced. When organizations engage with Y Prime, they have a dedicated support team that never changes. The people you work with from Day 1 will be there until completion of your project – no “knowledge transfers,” or redundant personnel required.  
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.y-prime.com
  • 263 Great Valley Parkway
    Malvern, PA USA 19355
  • Phone: 267.620.2000

Executives

Name Title Contact Details

Similar Companies

Quantom Genomics

Quantum Genomics is a biopharmaceutical company specializing in the development of a new drug class for unmet medical needs in cardiovascular disease, including high blood pressure and heart failure.

International Partnership for Microbicides

Developing HIV prevention products for women worldwide

Femme Pharma Global Healthcare Inc

Femme Pharma Global Healthcare Inc is a Wayne, PA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Daewoong Pharmaceutical Co.

Daewoong Pharmaceutical Co. is a Rockville, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Neurogastrx

We are a specialty pharmaceutical company developing transformative therapies to advance the treatment of gastrointestinal (GI) disorders. We focus on developing treatments for GI disorders for which meaningful therapeutic innovation is required to satisfy unmet patient need and disease burden. Our management team and board of directors are comprised of professionals with extensive backgrounds in drug research and development, commercialization, finance and business development for leading global pharmaceutical companies and growth-stage biopharmaceutical companies. Our scientific advisory board consists of well-known gastroenterologists and clinical thought leaders. Today, our pipeline consists of two unique clinical stage therapies with the potential to bring benefit to millions of patients with chronic and debilitating GI disorders that are not adequately controlled.